Int J Med Sci 2022; 19(3):486-487. doi:10.7150/ijms.71614 This issue Cite

Erratum

PRMT4 promotes hepatocellular carcinoma progression by activating AKT/mTOR signaling and indicates poor prognosis: Erratum

Peng Du, Kaifeng Luo, Guoyong Li, Jisheng Zhu, Qi Xiao, Yong Li, Xingjian Zhang

Department of General Surgery, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, China.

Citation:
Du P, Luo K, Li G, Zhu J, Xiao Q, Li Y, Zhang X. PRMT4 promotes hepatocellular carcinoma progression by activating AKT/mTOR signaling and indicates poor prognosis: Erratum. Int J Med Sci 2022; 19(3):486-487. doi:10.7150/ijms.71614. https://www.medsci.org/v19p0486.htm
Other styles

File import instruction

Corrected-article in Int J Med Sci, Volume 18, 3588


Citation styles

APA
Du, P., Luo, K., Li, G., Zhu, J., Xiao, Q., Li, Y., Zhang, X. (2022). PRMT4 promotes hepatocellular carcinoma progression by activating AKT/mTOR signaling and indicates poor prognosis: Erratum. International Journal of Medical Sciences, 19(3), 486-487. https://doi.org/10.7150/ijms.71614.

ACS
Du, P.; Luo, K.; Li, G.; Zhu, J.; Xiao, Q.; Li, Y.; Zhang, X. PRMT4 promotes hepatocellular carcinoma progression by activating AKT/mTOR signaling and indicates poor prognosis: Erratum. Int. J. Med. Sci. 2022, 19 (3), 486-487. DOI: 10.7150/ijms.71614.

NLM
Du P, Luo K, Li G, Zhu J, Xiao Q, Li Y, Zhang X. PRMT4 promotes hepatocellular carcinoma progression by activating AKT/mTOR signaling and indicates poor prognosis: Erratum. Int J Med Sci 2022; 19(3):486-487. doi:10.7150/ijms.71614. https://www.medsci.org/v19p0486.htm

CSE
Du P, Luo K, Li G, Zhu J, Xiao Q, Li Y, Zhang X. 2022. PRMT4 promotes hepatocellular carcinoma progression by activating AKT/mTOR signaling and indicates poor prognosis: Erratum. Int J Med Sci. 19(3):486-487.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.